Literature DB >> 1175883

Serum lysozyme in Crohn's disease. A useful index of disease activity.

K R Falchuk, J L Perrotto, K J Isselbacher.   

Abstract

Serum lysozyme concentrations were determined in patients with clinically active and inactive Crohn's disease as well as in healthy volunteers. The mean serum lysozyme concentrations (+/- SE) for each group were as follows: controls, 8.8 +/- 0.4; active Crohn's disease, 20.8 +/- 0.8; and inactive Crohn's disease, 10.4 +/- 0.7 mug per ml. The mean lysozyme level was significantly greater in active Crohn's disease as compared to normal subjects (P less than 0.001) and patients with inactive disease (P less than 0.001). Moreover, in patients with clinically severe Crohn's disease there seems to be a trend toward greater lysozyme levels, as opposed to those with mild to moderately active disease. In patients followed serially during the course of their disease, serum lysozyme levels increased with exacerbations of the illness and decreased with clinical improvement. These findings suggest that the serum lysozyme concentrations may serve as a useful index of the activity of Crohn's disease and aid in monitoring the clinical course of such patients.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1175883

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

1.  Serum lysozyme in inflammatory bowel and coeliac disease.

Authors:  E Mallas; J M Terry; P Asquith; W T Cooke
Journal:  J Clin Pathol       Date:  1976-07       Impact factor: 3.411

2.  Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis.

Authors:  K A Near; M J Lefford
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

3.  Circulating human leucocyte elastase in patients with inflammatory bowel disease.

Authors:  E O Adeyemi; S Neumann; V S Chadwick; H J Hodgson; M B Pepys
Journal:  Gut       Date:  1985-12       Impact factor: 23.059

Review 4.  Laboratory assessment of inflammatory bowel disease.

Authors:  I T Beck
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

5.  Serum lysozyme, serum proteins, and immunoglobulin determinations in nonspecific inflammatory bowel disease.

Authors:  O S El-Khatib; O Lebwohl; A A Attia; C A Flood; J A Stein; J G Sweeting; R T Whitlock; E F Osserman; P R Holt
Journal:  Am J Dig Dis       Date:  1978-04

6.  Muramidase (lysozyme) in Crohn's disease and in ulcerative colitis.

Authors:  W Pruzanski; N Marcon; C Ottaway; E Prokipchuk
Journal:  Am J Dig Dis       Date:  1977-11

Review 7.  Serum lysozyme levels in Crohn's disease and ulcerative colitis.

Authors:  T L Peeters; G Vantrappen; K Geboes
Journal:  Gut       Date:  1976-04       Impact factor: 23.059

8.  Immunohistochemical identification of lysozyme in intestinal lesions in ulcerative colitis and Crohn's disease.

Authors:  M Klockars; S Reitamo; J J Reitamo; C Möller
Journal:  Gut       Date:  1977-05       Impact factor: 23.059

9.  Platelet kinetics in Crohn's disease.

Authors:  G Bremer; E Jacobi; B Miller; H Ehms; G Strohmeyer
Journal:  Klin Wochenschr       Date:  1978-04-01

10.  A possible role for lysozyme in determining acute exacerbation in chronic bronchitis.

Authors:  D C Taylor; A W Cripps; R L Clancy
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.